Artículos por temáticas

Prospects of Marine Sterols against Pathobiology of Alzheimer's Disease: Pharmacological Insights and Technological Advances

Rahman MA, Dash R, Sohag AAM, Alam M, Rhim H, Ha H, Moon IS, Uddin MJ, Hannan MA.

Mar Drugs. 2021 Mar 20;19(3):167. doi: 10.3390/md19030167.

Melatonin Receptor as a Drug Target for Neuroprotection

Wongprayoon P, Govitrapong P.

Curr Mol Pharmacol. 2021;14(2):150-164. doi: 10.2174/1874467213666200421160835.

Pharmacological relevance of CDK inhibitors in Alzheimer's disease

Malhotra N, Gupta R, Kumar P.

Neurochem Int. 2021 Sep;148:105115. doi: 10.1016/j.neuint.2021.105115. Epub 2021 Jun 25.

Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches

Cruz-Vicente P, Passarinha LA, Silvestre S, Gallardo E.

Molecules. 2021 Apr 11;26(8):2193. doi: 10.3390/molecules26082193.

An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure

Boopathi S, Poma AB, Garduño-Juárez R.

Int J Mol Sci. 2021 Oct 6;22(19):10798. doi: 10.3390/ijms221910798.

Therapeutic potential of catalpol and geniposide in Alzheimer's and Parkinson's diseases: A snapshot of their underlying mechanisms

Zhang X, Liu K, Shi M, Xie L, Deng M, Chen H, Li X.

Brain Res Bull. 2021 Sep;174:281-295. doi: 10.1016/j.brainresbull.2021.06.020. Epub 2021 Jul 1.

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review

Łukasik P, Załuski M, Gutowska I.

Int J Mol Sci. 2021 Mar 13;22(6):2935. doi: 10.3390/ijms22062935.

Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders

Saha S, Pal D, Nimse SB.

Curr Drug Targets. 2021;22(12):1437-1462. doi: 10.2174/1389450122666210120143953.

Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)

Ferreira JPS, Albuquerque HMT, Cardoso SM, Silva AMS, Silva VLM.

Eur J Med Chem. 2021 Oct 5;221:113492. doi: 10.1016/j.ejmech.2021.113492. Epub 2021 Apr 24.

Icariin ameliorate Alzheimer's disease by influencing SIRT1 and inhibiting Aβ cascade pathogenesis

Chuang Y, Van I, Zhao Y, Xu Y.

J Chem Neuroanat. 2021 Nov;117:102014. doi: 10.1016/j.jchemneu.2021.102014. Epub 2021 Aug 15.

Rapid drug access and scientific rigour: a delicate balance

The Lancet Neurology.

Lancet Neurol. 2021 Jan;20(1):1. doi: 10.1016/S1474-4422(20)30452-X.

Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review

Malafaia D, Albuquerque HMT, Silva AMS.

Eur J Med Chem. 2021 Mar 15;214:113209. doi: 10.1016/j.ejmech.2021.113209. Epub 2021 Jan 25.

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease

Kim J.

Int J Mol Sci. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929.

Update and Potential Opportunities in CBP [Cyclic Adenosine Monophosphate (cAMP) Response Element-Binding Protein (CREB)-Binding Protein] Research Using Computational Techniques

Akinsiku OE, Soremekun OS, Soliman MES.

Protein J. 2021 Feb;40(1):19-27. doi: 10.1007/s10930-020-09951-8. Epub 2021 Jan 4.

Role of Receptors in Relation to Plaques and Tangles in Alzheimer's Disease Pathology

Sharma K, Pradhan S, Duffy LK, Yeasmin S, Bhattarai N, Schulte MK.

Int J Mol Sci. 2021 Nov 30;22(23):12987. doi: 10.3390/ijms222312987.